替罗非班对急性冠脉综合征患者血清C-反应蛋白的影响

Effect of tirofiban on the serum C-reactive protein in patients with acute coronary syndrome

目的:应用替罗非班治疗急性冠脉综合征(acute coronary syndrome,ACS),以观察其对患者血清C-反应蛋白(C-reactive protein,CRP)的影响。方法:选择63例急性冠脉综合征患者分成观察组、对照组。入院后常规扩冠、抗凝、抗血小板聚集治疗,观察组同时给予替罗非班治疗。于治疗前后分别检测CRP,进行对比分析。结果:2组ACS患者经4周治疗后CRP下降(P<0.01)。与对照组比较,观察组血清CRP水平下降明显,尤以治疗后4周最为明显(P<0.01)。2组患者均未见出血并发症。结论:替罗非班能明显降低血清CRP,抑制斑块内炎症反应,有效改善ACS,且不增加出血的危险,适于临床应用。

OBJECTIVE To treat acute coronary syndrome（ACS） patients with tirofiban in order to observe its effect on the serum C-reactive protein（CRP） in them. METHODS Sixty-three patients with ACS were randomly divided into observed group and control group. All the patients were treated routinely through dilatation of coronary arteries, anticoagulation and anti-platelet aggregation after hospitalization. Patients in the observed group were treated with tirofiban at the same time. Serum levels of CRP were determined before and after treatment respectively. The results were compared and analysed. RESULTS Serum CRP in ACS patients in both groups declined after 4 weeks of treatment （P〈0.01）. Compared with those in the control group, CRP levels in the observed group declined significantly, and most significantly four weeks after treatment（P〈0. 01）. Hemorrhagic complications were not observed in both the groups. CONCLUSION Tirofiban can lower serum CRP significantly and inhibit the inflammatory reaction within atheromatous plaques, It thus can improve ACS effectively without increased risk for hemorrhages, onsequently tirofiban is fit for clinical application.